News GSK plc

Equities

GSK

GB00BN7SWP63

Real-time Estimate Cboe Europe Other stock markets 05:39:20 2024-04-18 am EDT			5-day change	1st Jan Change
1,588 ^GBX	-0.09%		-2.64%	+9.36%

Apr. 17	GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix	MT
Apr. 17	GSK: positive clinical results for gonorrhea	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments \| GSK	Apr. 17	AQ
New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade \| GSK	Apr. 17	AQ
GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix	Apr. 17	MT
GSK: positive clinical results for gonorrhea	Apr. 17	CF
GSK : EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments - Form 6-K	Apr. 17	PU
Gsk plc Announces New Long-Term Data Show Shingrix Continues to Provide High Protection Against Shingles in Adults Aged 50 and over for More Than A Decade	Apr. 17	CI
GSK: shingles virus effective for over 10 years	Apr. 17	CF
GSK's 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA \| GSK	Apr. 17	AQ
GSK hails data on Shingles vaccine and gonorrhoea treatment	Apr. 17	AN
GSK's Uncomplicated Urogenital Gonorrhea Treatment Meets Primary Endpoint in Late-stage Trial	Apr. 17	MT
GSK's Shingles Vaccine Shows High Efficacy Among Older Adults in 11-Year Follow-Up Trial	Apr. 17	MT
GSK : EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments	Apr. 17	PU
GSK : New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade	Apr. 17	PU
GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin	Apr. 17	CI
China GDP Beat Fails to Boost Sentiment as UK's FTSE 100 Index Sheds Nearly 2%	Apr. 16	MT
GSK Says US FDA Accepts Meningococcal Vaccine Candidate for Regulatory Review	Apr. 16	MT
GSK : 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA - Form 6-K	Apr. 16	PU
GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY Vaccine Candidate	Apr. 16	CI
GSK: vaccine accepted for FDA review	Apr. 16	CF
GSK's latest meningitis vaccine accepted for review by US regulator	Apr. 16	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK PLC : 2023 ended on a strong note; medium- to long-term guidance raised

February 02, 2024 at 09:40 am EST